Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/58942

Type
Article
Copyright
Open access
Sustainable Development Goals
03 Saúde e Bem-Estar
Collections
Share

Statistics
Metadata
Show full item record

BRIDGING THE IMMUNOGENICITY OF A TETRAVALENT DENGUE VACCINE (TAK-003) FROM CHILDREN AND ADOLESCENTS TO ADULTS
LeFevre, Inge et al. | Date Issued: 2023
Author
LeFevre, Inge
Bravo, Lulu
Folschweiller, Nicolas
Medina, Eduardo Lopez
Moreira Jr, Edson Duarte
Nordio, Francesco
Sharma, Mayuri
Tharenos, Leslie M.
Tricou, Vianney
Watanaveeradej, Veerachai
Winkle, Peter J.
Biswal, Shibadas
Affilliation
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
University of the Philippines. College of Medicine. Manila, Philippines.
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
Universidad Del Valle. Centro de Estudios en Infectología Pediatrica CEIP. Department of Pediatrics. Clínica Imbanaco. Grupo Quironsalud. Cali, Colombia.
Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Associação Obras Sociais Irmã Dulce Hospital Santo Antônio. Salvador, BA, Brasil.
Takeda Vaccines Inc. Cambridge, MA, USA.
Takeda Vaccines Inc. Cambridge, MA, USA.
The Division of Environmental and Occupational Health Sciences. University of Illinois at Chicago School of Public Health. Chicago, IL, USA.
Vaccines Business Unit. Takeda Pharmaceuticals International AG. Zürich, Switzerland.
Department of Pediatrics. Phramongkutklao Hospital and Faculty of Medicine. Kasetsart University. Bangkok, Thailand.
Anaheim Clinical Trials. Anaheim, CA, USA.
Takeda Vaccines Inc. Cambridge, MA, USA.
Abstract
Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic to many tropical and subtropical regions, is traditionally thought of as a pediatric disease but is now a global threat to both children and adults. We bridged immunogenicity data from a phase 3 efficacy study of a tetravalent dengue vaccine (TAK-003), performed in children and adolescents living in endemic areas, with an immunogenicity study in adults in non-endemic areas. Neutralizing antibody responses were comparable in both studies following receipt of a two-dose TAK-003 schedule (months 0 and 3). Similar immune responses were observed across exploratory assessments of additional humoral responses. These data support the potential for clinical efficacy of TAK-003 in adults.
Keywords in Portuguese
Imunogenicidade
Vacina tetravalente
Dengue (TAK-003)
Crianças
Adolescentes
Adultos
 
Keywords
Immunogenicity
Tetravalent vaccine
Dengue (TAK-003)
Children
Adolescents
Adults
 
DeCS
Imunogenicidade da vacina
Vacinas combinadas
Dengue
Criança
Adolescente
Adulto
 
Publisher
Nature Research
Citation
LEFEVRE, Inge et al. Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults. npj Vaccines, v. 75, p. 1-9, 2023.
DOI
10.1038/s41541-023-00670-6
ISSN
2059-0105